AVALYN PHARMA INC (AVLN)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
Early-stage biopharmaceutical company developing novel therapeutic candidates across multiple disease indications.
What AVALYN PHARMA INC does
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates designed to address unmet medical needs across multiple disease indications. The company conducts preclinical studies and clinical trials to advance its pipeline of product candidates through regulatory development. Avalyn relies on third-party contract research organizations for clinical trial execution and manufacturing partners for product candidate production. The company is pursuing regulatory approvals and commercialization strategies for its investigational therapeutics.
Themes: ["clinical-stage development","drug candidate advancement","regulatory pathway"]
Fundamentals
- Price$28.92 as of 2026-07-09 close
- Market cap$1.3B as of 2026-07-10
- 1-year return-1.9% as of 2026-07-09 close
- ROE-63.8% as of 2026-07-10
- Debt / equity0.14 as of 2026-07-10
- Beta0.17 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial execution risks and uncertainty in demonstrating safety and efficacy of product candidates","Dependence on third-party contract research organizations and manufacturing partners for critical development and production activities","Significant ongoing R&D costs and need for additional financing to support clinical programs and operations"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.